These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

342 related items for PubMed ID: 8530634

  • 21. Evidence against depletion of the growth hormone (GH)-releasable pool in human primary hypothyroidism: studies with GH-releasing hormone, pyridostigmine, and arginine.
    Valcavi R, Valente F, Dieguez C, Zini M, Procopio M, Portioli I, Ghigo E.
    J Clin Endocrinol Metab; 1993 Sep; 77(3):616-20. PubMed ID: 8103770
    [Abstract] [Full Text] [Related]

  • 22. Arginine normalizes the growth hormone (GH) response to GH-releasing hormone in adult patients receiving chronic daily immunosuppressive glucocorticoid therapy.
    Giustina A, Bossoni S, Bodini C, Girelli A, Balestrieri GP, Pizzocolo G, Wehrenberg WB.
    J Clin Endocrinol Metab; 1992 Jun; 74(6):1301-5. PubMed ID: 1592874
    [Abstract] [Full Text] [Related]

  • 23. Somatotrope responsiveness to Hexarelin, a synthetic hexapeptide, is refractory to the inhibitory effect of glucose in obesity.
    Grottoli S, Maccario M, Procopio M, Oleandri SE, Arvat E, Gianotti L, Deghenghi R, Camanni F, Ghigo E.
    Eur J Endocrinol; 1996 Dec; 135(6):678-82. PubMed ID: 9025712
    [Abstract] [Full Text] [Related]

  • 24. Short term continuous intravenous infusion of growth hormone (GH) inhibits GH-releasing hormone-induced GH secretion: a time-dependent effect.
    Rosenthal SM, Kaplan SL, Grumbach MM.
    J Clin Endocrinol Metab; 1989 Jun; 68(6):1101-5. PubMed ID: 2498383
    [Abstract] [Full Text] [Related]

  • 25. Cholinergic control of growth hormone (GH) responses to GH-releasing hormone in insulin dependent diabetics: evidence for attenuated hypothalamic somatostatinergic tone and decreased GH autofeedback.
    Ismail IS, Scanlon MF, Peters JR.
    Clin Endocrinol (Oxf); 1993 Feb; 38(2):149-57. PubMed ID: 8094648
    [Abstract] [Full Text] [Related]

  • 26. Studies of growth hormone secretion in calorically restricted dogs: effect of cholinergic agonists and antagonists, glucose and thyrotropin-releasing hormone.
    Arce VM, Cella SG, Locatelli V, Müller EE.
    Neuroendocrinology; 1991 May; 53(5):467-72. PubMed ID: 1908062
    [Abstract] [Full Text] [Related]

  • 27. Radiation and neuroregulatory control of growth hormone secretion.
    Ogilvy-Stuart AL, Wallace WH, Shalet SM.
    Clin Endocrinol (Oxf); 1994 Aug; 41(2):163-8. PubMed ID: 7923820
    [Abstract] [Full Text] [Related]

  • 28. Effects of acipimox, an antilipolytic drug, on the growth hormone (GH) response to GH-releasing hormone alone or combined with arginine in obesity.
    Maccario M, Procopio M, Grottoli S, Oleandri SE, Boffano GM, Taliano M, Camanni F, Ghigo E.
    Metabolism; 1996 Mar; 45(3):342-6. PubMed ID: 8606641
    [Abstract] [Full Text] [Related]

  • 29. Impaired inhibitory effects of somatostatin on growth hormone (GH)-releasing hormone stimulation of GH secretion after short term infusion.
    Kelijman M, Frohman LA.
    J Clin Endocrinol Metab; 1990 Jul; 71(1):157-63. PubMed ID: 1973420
    [Abstract] [Full Text] [Related]

  • 30. Plasma concentrations of growth hormone during hyperglycemic clamp with or without somatostatin infusion in obese subjects.
    Bonora E, Moghetti P, Zenere M, Querena M, Tosi F, Corgnati A, Muggeo M.
    J Clin Endocrinol Metab; 1990 Jun; 70(6):1732-4. PubMed ID: 1971827
    [Abstract] [Full Text] [Related]

  • 31. Effects of dexamethasone on growth hormone (GH)-releasing hormone, arginine- and dopaminergic stimulated GH secretion, and total plasma insulin-like growth factor-I concentrations in normal male volunteers.
    Miell JP, Corder R, Pralong FP, Gaillard RC.
    J Clin Endocrinol Metab; 1991 Mar; 72(3):675-81. PubMed ID: 1671785
    [Abstract] [Full Text] [Related]

  • 32. Effects of recombinant human insulin-like growth factor I administration on growth hormone (GH) secretion, both spontaneous and stimulated by GH-releasing hormone or hexarelin, a peptidyl GH secretagogue, in humans.
    Ghigo E, Gianotti L, Arvat E, Ramunni J, Valetto MR, Broglio F, Rolla M, Cavagnini F, Müller EE.
    J Clin Endocrinol Metab; 1999 Jan; 84(1):285-90. PubMed ID: 9920097
    [Abstract] [Full Text] [Related]

  • 33. Effects of cholinergic muscarinic antagonist pirenzepine on GH response to GHRH 1-40 in patients with anorexia nervosa.
    Rolla M, Andreoni A, Belliti D, Ferdeghini M, Cristofani R, Müller EE.
    Endocrinol Exp; 1990 Mar; 24(1-2):195-204. PubMed ID: 2113857
    [Abstract] [Full Text] [Related]

  • 34. Reduction of the somatotrope responsiveness to GHRH and Hexarelin but not to arginine plus GHRH in hyperprolactinemic patients.
    Grottoli S, Razzore P, Arvat E, Oleandri SE, Rossetto R, Ciccarelli E, Camanni F, Ghigo E.
    J Endocrinol Invest; 1997 Nov; 20(10):597-602. PubMed ID: 9438917
    [Abstract] [Full Text] [Related]

  • 35. Arginine counteracts the inhibitory effect of recombinant human insulin-like growth factor I on the somatotroph responsiveness to growth hormone-releasing hormone in humans.
    Gianotti L, Maccario M, Lanfranco F, Ramunni J, Di Vito L, Grottoli S, Muller EE, Ghigo E, Arvat E.
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3604-8. PubMed ID: 11061509
    [Abstract] [Full Text] [Related]

  • 36. Effect of withdrawal of somatostatin plus GH-releasing hormone as a stimulus of GH secretion in obesity.
    Alvarez P, Isidro L, Leal-Cerro A, Casanueva FF, Dieguez C, Cordido F.
    Clin Endocrinol (Oxf); 2002 Apr; 56(4):487-92. PubMed ID: 11966741
    [Abstract] [Full Text] [Related]

  • 37. The decrease in growth hormone (GH) response after repeated stimulation with GH-releasing hormone is partly caused by an elevation of somatostatin tonus.
    Reichardt B, Schrader M, Mojto J, Mehltretter G, Müller OA, Schopohl J.
    J Clin Endocrinol Metab; 1996 May; 81(5):1994-8. PubMed ID: 8626871
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Activation of cholinergic neurotransmission by pyridostigmine reverses the inhibitory effect of hyperglycemia on growth hormone (GH) releasing hormone-induced GH secretion in man: does acute hyperglycemia act through hypothalamic release of somatostatin?
    Peñalva A, Burguera B, Casabiell X, Tresguerres JA, Dieguez C, Casanueva FF.
    Neuroendocrinology; 1989 May; 49(5):551-4. PubMed ID: 2566942
    [Abstract] [Full Text] [Related]

  • 40. Further evidence of cholinergic impairment of the neuroendocrine control of the GH secretion in Down's syndrome.
    Beccaria L, Marziani E, Manzoni P, Arvat E, Valetto MR, Gianotti L, Ghigo E, Chiumello G.
    Dement Geriatr Cogn Disord; 1998 May; 9(2):78-81. PubMed ID: 9524798
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.